Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer Journal Article


Authors: Rathkopf, D.; Liu, G.; Carducci, M. A.; Eisenberger, M. A.; Anand, A.; Morris, M. J.; Slovin, S. F.; Sasaki, Y.; Takahashi, S.; Ozono, S.; Fung, N. K. E.; Cheng, S.; Gan, J.; Gottardis, M.; Obermeier, M. T.; Reddy, J.; Zhang, S.; Vakkalagadda, B. J.; Alland, L.; Wilding, G.; Scher, H. I.
Article Title: Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer
Abstract: Purpose: BMS-641988 is an androgen receptor antagonist with increased potency relative to bicalutamide in both in vitro and in vivo prostate cancer models. A first-in-man phase I study was conducted to define the safety and tolerability of oral BMS-641988 in patients with castration-resistant prostate cancer (CRPC). Experimental Design: Doses were escalated from 5 to 150 mg based on discrete pharmacokinetic parameters in cohorts of three to six subjects. After establishing safety with 20 mg of BMS-641988 in the United States, a companion study was opened in Japan to assess differences in drug metabolism between populations. Results: Sixty-one men with CRPC were treated with daily BMS-641988. The pharmacokinetics (PK) of BMS-641988 and its active metabolites were proportional to dose. One patient experienced an epileptic seizure at a dose of 60 mg administered twice. Despite achieving target drug exposures, antitumor activity was limited to one partial response. Seventeen of 23 evaluable patients (74%) exhibited stable disease on imaging (median 15 weeks; range 8-32), and 10 of 61 patients (16%) achieved a ≥30% decline in levels of prostate-specific antigen (PSA). Partial agonism was seen within the context of this study upon removal of the drug as evidenced by a decrease in PSA. Conclusions: Although the clinical outcomes of predominantly stable disease and partial agonism were similar to what was observed in the preclinical evaluation of the compound, the limited antitumor activity of BMS-641988 at therapeutic dose levels coupled with an episode of seizure activity led to study closure. ©2010 AACR.
Keywords: adult; treatment response; aged; unclassified drug; major clinical study; constipation; drug tolerability; fatigue; area under the curve; diarrhea; drug safety; hypertension; side effect; united states; outcome assessment; antineoplastic agent; anorexia; prostate specific antigen; edema; infection; neutrophil count; pain; sensory neuropathy; gastrointestinal symptom; mucosa inflammation; nausea; randomized controlled trial; thrombocytopenia; vomiting; myalgia; qt prolongation; antineoplastic activity; docetaxel; arthralgia; dizziness; drug dose escalation; prostate cancer; rash; drug response; xerostomia; pleura effusion; seizure; hot flush; drug metabolism; phase 1 clinical trial; antiandrogen; drug metabolite; epilepsy; double blind procedure; dyspepsia; flatulence; japanese; japan; drug exposure; blurred vision; bms 641988; hyperhidrosis; castration resistant prostate cancer; weight; decreased appetite; eructation; bms 501949; bms 570511; consciousness disorder; dry throat; hypersalivation; musculoskeletal stiffness; partial agonism
Journal Title: Clinical Cancer Research
Volume: 17
Issue: 4
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2011-02-15
Start Page: 880
End Page: 887
Language: English
DOI: 10.1158/1078-0432.ccr-10-2955
PROVIDER: scopus
PMCID: PMC3070382
PUBMED: 21131556
DOI/URL:
Notes: --- - "Export Date: 23 June 2011" - "CODEN: CCREF" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Susan Slovin
    254 Slovin
  2. Michael Morris
    577 Morris
  3. Dana Elizabeth Rathkopf
    272 Rathkopf
  4. Howard Scher
    1130 Scher
  5. Aseem Anand
    61 Anand